Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- PMDA Reviewing Daklinza, Sunvepra for Risk of Interstitial Pneumonia
September 28, 2015
- MHLW OKs New Indications for Xarelto, Lamictal, Other Products
September 25, 2015
- Drug Pricing Tomorrow: Full Interview with MOF Budget Examiner Unami
September 25, 2015
- One-Month Lag in Regulatory Filing Accepted for Sakigake Designation
September 24, 2015
- Pharmaceutical Affairs Council Approves Basic Plan for “Humanitarian Trials”
September 24, 2015
- Panel OKs Revised Japanese Pharmacopoeia, 76 Products Newly Included
September 18, 2015
- MHLW to Continue to Suspend HPV Vaccine Recommendation
September 18, 2015
- 51 Products Officially Filed for Sakigake Designation after MHLW Screening
September 18, 2015
- Add Myasthenia Gravis, Myositis to Opdivo Label: MHLW
September 17, 2015
- Toxic Epidermal Necrolysis Added to Clinically Significant ADR List for Vectibix
September 17, 2015
- Editor’s Pick: Five Healthcare News Headlines for August 24 - September 13
September 15, 2015
- Japan to Help Fight Infectious Diseases in Developing Nations: Basic Policy
September 15, 2015
- Bevacizumab, 2 Other Compounds Designated as Orphan Drugs
September 15, 2015
- Kaketsuken Reports Results of Internal Probe on Improper Blood Product Manufacturing
September 11, 2015
- 1 Million Signatures Collected Opposing Exclusion of Kampo from Reimbursement; “Discussion Closed”: LDP Kampo Supporters
September 11, 2015
- MHLW Reports on “Comprehensive Strategy” at Chuikyo
September 10, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 2
September 10, 2015
- Drug Pricing Tomorrow: MOF Budget Examiner Eyes “Sharp Price Cuts” for Both New and Listed Generics in 2016
September 9, 2015
- MHLW Launches Office to Promote Genomic Medicine
September 9, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 1
September 9, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…